Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants

被引:33
作者
Jensen, MJ [1 ]
Smith, TJ [1 ]
Ahmed, SA [1 ]
Smith, LA [1 ]
机构
[1] USA, Med Res Inst Infect Dis, Div Toxicol & Aerobiol, Ft Detrick, MD 21702 USA
关键词
neurotoxin; Clostridium botulinum; light chain; protein expression;
D O I
10.1016/S0041-0101(03)00042-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Clostridial neurotoxins are potent inhibitors of synaptic function, with the zinc-dependent proteolytic light chain (LC) portion of the toxin cleaving one of three neural SNARE proteins. In nature, the LC is expressed as a part of a much larger toxin and hemagglutinin complex, protecting it from environmental degradation and preserving its catalytic activity. We developed forms of the LC of type A botulinum neurotoxin (BoNT-A) with parts of the larger toxin gene, for use as reagents in high-throughput assays to screen for potential LC antagonists, to further elucidate the toxin's mechanism of action, and to study immunological responses to the toxin. Three BoNT-A constructs were engineered and expressed: the LC, LC with translocation region (LC + H-n), and the LC with the belt portion of the translocation region (LC + Belt). Purification was optimized to a two-step process, with relatively high yields of all three constructs obtained. Activity assays showed all three constructs to be active, with the LC being the most active. Immunogenic protection against native BoNT-A toxin challenge was observed for all three constructs, with the best protection observed with the LC + Hn and LC + Belt proteins. Published by Elsevier Science Ltd.
引用
收藏
页码:691 / 701
页数:11
相关论文
共 39 条
  • [1] Enzymatic autocatalysis of botulinum a neurotoxin light chain
    Ahmed, SA
    Byrne, MP
    Jensen, M
    Hines, HB
    Brueggemann, E
    Smith, LA
    [J]. JOURNAL OF PROTEIN CHEMISTRY, 2001, 20 (03): : 221 - 231
  • [2] Light chain of botulinum a neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active
    Ahmed, SA
    Smith, LA
    [J]. JOURNAL OF PROTEIN CHEMISTRY, 2000, 19 (06): : 475 - 487
  • [3] BITTNER MA, 1989, J BIOL CHEM, V264, P10354
  • [4] BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25
    BLASI, J
    CHAPMAN, ER
    LINK, E
    BINZ, T
    YAMASAKI, S
    DECAMILLI, P
    SUDHOF, TC
    NIEMANN, H
    JAHN, R
    [J]. NATURE, 1993, 365 (6442) : 160 - 163
  • [5] Electron density projection map of the botulinum neurotoxin 900-kilodalton complex by electron crystallography
    Burkard, F
    Chen, F
    Kuziemko, GM
    Stevens, RC
    [J]. JOURNAL OF STRUCTURAL BIOLOGY, 1997, 120 (01) : 78 - 84
  • [6] Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate
    Byrne, MP
    Smith, TJ
    Montgomery, VA
    Smith, LA
    [J]. INFECTION AND IMMUNITY, 1998, 66 (10) : 4817 - 4822
  • [7] Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris
    Byrne, MP
    Titball, RW
    Holley, J
    Smith, LA
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 2000, 18 (03) : 327 - 337
  • [8] Development of vaccines for prevention of botulism
    Byrne, MP
    Smith, LA
    [J]. BIOCHIMIE, 2000, 82 (9-10) : 955 - 966
  • [9] Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A
    Chaddock, JA
    Herbert, MH
    Ling, RJ
    Alexander, FCG
    Fooks, SJ
    Revell, DF
    Quinn, CP
    Shone, CC
    Foster, KA
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 2002, 25 (02) : 219 - 228
  • [10] PROTECTIVE VACCINATION WITH A RECOMBINANT FRAGMENT OF CLOSTRIDIUM-BOTULINUM NEUROTOXIN SEROTYPE A EXPRESSED FROM A SYNTHETIC GENE IN ESCHERICHIA-COLI
    CLAYTON, MA
    CLAYTON, JM
    BROWN, DR
    MIDDLEBROOK, JL
    [J]. INFECTION AND IMMUNITY, 1995, 63 (07) : 2738 - 2742